Graft versus Leukemia Could Participate of Efficacy of Blinatumomab in Patients with B-Lineage Acute Lymphoid Leukemia Relapsing after Stem Cell Transplantation

Ronchetti, Anne Marie

doi:10.4172/2157-7633.1000251

Cited by 1 publication

(1 citation statement)

References 14 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Several reports have also supported the effectiveness of blinatumomab for the patients with B-ALL (Table 1) [30][31][32]. The case study using blinatumomab and DLI after the second allo-HSCT for a patient with precursor B-ALL demonstrated that the patient achieved MRD-negative CR 7 months after initiating blinatumomab without extramedullary relapse or blinatumomab-related toxicities [33].…”

Section: Discussionmentioning

confidence: 94%

Concomitant use of blinatumomab and donor lymphocyte infusion for mixed-phenotype acute leukemia: a case report with literature review

Durer

Shafqat

et al. 2019

Immunotherapy

View full text Add to dashboard Cite

Blinatumomab and donor lymphocyte infusion (DLI) combination is a promising cancer therapy, whereby blinatumomab might achieve an initial reduction in leukemic-cell burden using T cells, and after tumor clearance, DLI can potentially stimulate the donor immune system to achieve longer lasting remission. Here, we present a 51-year-old female with mixed phenotype acute leukemia who had a hematologic relapse 3 months after she received total body irradiation-based myeloablative allogeneic hematopoietic stem cell transplantation from an unrelated human leukocyte antigen matched (10/10) donor and achieved complete remission with minimal residual disease negativity by multi-parameter flow cytometry using the combination of blinatumomab and DLI. To the best of our knowledge, this is the first report to describe the use of blinatumomab and DLI combination therapy in the treatment of B/myeloid mixed phenotype acute leukemia.

show abstract

Section: Discussionmentioning

confidence: 94%